Esophageal Adenocarcinoma — Trials

Esophageal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 70
Recruiting: 45
Ph III recruiting: 4
Growth YoY: —
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (27)

clinicaltrialsPublishedShowing 1–9 of 9 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06585488	A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification	terminated	Phase 1	47	BeOne MedicinesINDUSTRY	5	Jul 8, 2026	clinicaltrials
NCT06560645	A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation	terminated	Phase 1	42	Prelude TherapeuticsINDUSTRY	6	Feb 2, 2026